First Trust Advisors LP Lowers Stock Holdings in Novo Nordisk A/S $NVO

Key Points

• First Trust Advisors LP cut its Novo Nordisk stake by 94.5% in the first quarter, selling 476,069 shares and retaining 27,466 shares valued at approximately $1.01 million.
• Novo Nordisk shares were trading at $47.59, while the company reported quarterly revenue of $11.98 billion and earnings of $0.94 per share. Institutional investors collectively own 11.54% of the stock.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target near $65.81. The company also announced a $0.5786 dividend, with a 42.79% payout ratio.

First Trust Advisors LP reduced its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 94.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,466 shares of the company's stock after selling 476,069 shares during the quarter. First Trust Advisors LP's holdings in Novo Nordisk A/S were worth $1,009,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Boston Partners bought a new stake in Novo Nordisk A/S in the third quarter worth $310,199,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company's stock valued at $492,940,000 after acquiring an additional 4,836,285 shares in the last quarter. Voloridge Investment Management LLC increased its holdings in shares of Novo Nordisk A/S by 851.6% during the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company's stock valued at $244,594,000 after acquiring an additional 4,302,126 shares in the last quarter. Bank of Montreal Can raised its position in shares of Novo Nordisk A/S by 138.9% in the 4th quarter. Bank of Montreal Can now owns 2,525,827 shares of the company's stock worth $128,514,000 after purchasing an additional 1,468,409 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new position in Novo Nordisk A/S in the 4th quarter worth about $59,882,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 0.7%

NYSE:NVO opened at $47.59 on Tuesday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a market cap of $212.49 billion, a PE ratio of 11.64, a price-to-earnings-growth ratio of 4.31 and a beta of 0.76. The company has a 50 day simple moving average of $47.07 and a two-hundred day simple moving average of $44.81.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The firm had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. Research analysts forecast that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be given a $0.5786 dividend. This represents a yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 42.79%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Weiss Ratings raised shares of Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Friday, June 19th. Zacks Research cut shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Monday, July 13th. HSBC restated a "hold" rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Finally, Wall Street Zen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. Five equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $65.81.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Analysts set an average price target of $65.56 for Novo Nordisk, implying substantial upside from recent trading levels. The target reflects continued confidence in the company’s earnings power and obesity- and diabetes-drug franchise. Analysts Set Novo Nordisk A/S Price Target at $65.56
• Positive Sentiment: Novo Nordisk named Amazon Web Services its preferred global cloud and strategic AI partner. The companies are establishing a London innovation hub, with AWS tools supporting drug-target identification, therapy design and clinical-data analysis; more than 25,000 Novo employees have already used the collaboration’s tools. Faster discovery and development could improve long-term pipeline productivity. Novo Nordisk, Amazon Web Services Collaborate to Advance Drug Discovery
• Positive Sentiment: Veru’s semaglutide combination trial is fully enrolled and is proceeding under a clinical supply agreement with Novo Nordisk. The arrangement provides additional validation for semaglutide’s role in future weight-loss therapies, although the trial is still early-stage and results are not expected until the first quarter of 2027. Veru Reports Fiscal 2026 Third Quarter Financial Results
• Neutral Sentiment: Industry coverage highlights manufacturing capacity as an increasingly important competitive advantage in the obesity-drug market. Novo is competing with Eli Lilly on production scale, supply reliability and commercial execution, keeping the company’s long-term opportunity significant but highly competitive. Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?
• Negative Sentiment: Hims’ restructuring and move away from compounded GLP-1 medications could reduce one source of demand for compounded alternatives, while underscoring the regulatory and competitive risks surrounding the broader weight-loss-drug market. The impact on Novo is indirect. Hims Stock Falls on Earnings

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source